Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Apr;29(4):2047-2055.
doi: 10.1007/s00520-020-05693-6. Epub 2020 Aug 27.

The short-term impact of methylprednisolone on patient-reported sleep in patients with advanced cancer in a randomized, placebo-controlled, double-blind trial

Gunnhild Jakobsen  1   2 , Morten Engstrøm  3   4 , Marianne Jensen Hjermstad  5   6   7 , Jan Henrik Rosland  8   9 , Nina Aass  5   10 , Eva Albert  11 , Stein Kaasa  12   6   7 , Peter Fayers  13 , Pål Klepstad  14   15 , Ørnulf Paulsen  6   7   16
Affiliations
Randomized Controlled Trial

The short-term impact of methylprednisolone on patient-reported sleep in patients with advanced cancer in a randomized, placebo-controlled, double-blind trial

Gunnhild Jakobsen et al. Support Care Cancer. 2021 Apr.

Abstract

Purpose: Although corticosteroids are frequently used in patients with advanced cancer, few studies have examined the impact of these drugs on patient-reported sleep. We aimed to examine the short-term impact of methylprednisolone on patient-reported sleep in patients with advanced cancer.

Methods: Patient-reported sleep was a predefined secondary outcome in a prospective, randomized, placebo-controlled, double-blind trial that evaluated the analgesic efficacy of corticosteroids in advanced cancer patients (18+), using opioids, and having pain ≥ 4 past 24 h (NRS 0-10). Patients were randomized to the methylprednisolone group with methylprednisolone 16 mg × 2/day or placebo for 7 days. The EORTC QLQ-C30 (0-100) and the Pittsburgh Sleep Quality Index questionnaire (PSQI) (0-21) were used to assess the impact of corticosteroids on sleep at baseline and at day 7.

Results: Fifty patients were randomized of which 25 were analyzed in the intervention group and 22 in the control group. Mean age was 64 years, mean Karnofsky performance status was 67 (SD 13.3), 51% were female, and the mean oral daily morphine equivalent dose was 223 mg (SD 222.77). Mean QLQ-C30 sleep score at baseline was 29.0 (SD 36.7) in the methylprednisolone group and 24.2 (SD 27.6) in the placebo group. At day 7, there was no difference between the groups on QLQ-C30 sleep score (methylprednisolone 20.3 (SD 32.9); placebo 28.8 (SD 33.0), p = 0.173). PSQI showed similar results.

Conclusions: Methylprednisolone 16 mg twice daily for 7 days had no impact on patient-reported sleep in this cohort of patients with advanced cancer.

Trial registration: Clinical trial information NCT00676936 (13.05.2008).

Keywords: Advanced cancer; Corticosteroids; Randomized controlled trial; Sleep.

PubMed Disclaimer

Conflict of interest statement

Marianne Jensen Hjermstad, Jan Henrik Rosland, Nina Aass, Eva Albert, Peter Fayers, and Pål Klepstad have nothing to disclose. Ørnulf Paulsen has received PhD grant from the Telemark Hospital Trust and the South-Eastern Norway Regional Health Authority. Gunnhild Jakobsen has received PhD grant from the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU). Morten Engstrøm has received lecture fees and support for travel from ResMed and Philips. Stein Kaasa is one of the shareholders in Eir Solution A/S and has research funding from Nutricia for other studies. The authors declare no income, dividend, or financial benefits from the work presented here.

Figures

Fig. 1
Fig. 1
CONSORT flow diagram of the progress through the phases of the trial. The figure reports the essentials for analysis of sleep and is adapted from the diagram in the original trial [27]
Fig. 2
Fig. 2
Mean score of QLQ-C30 sleep item according to treatment arm. A higher score represents more sleeping trouble. There were no statistically significant difference in change of sleep problems between the treatment arms (error bars 95% CI)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Otte JL, Carpenter JS, Manchanda S, Rand KL, Skaar TC, Weaver M, Chernyak Y, Zhong X, Igega C, Landis C. Systematic review of sleep disorders in cancer patients: can the prevalence of sleep disorders be ascertained? Cancer medicine. 2015;4:183–200. doi: 10.1002/cam4.356. - DOI - PMC - PubMed
    1. Akman T, Yavuzsen T, Sevgen Z, Ellidokuz H, Yilmaz AU. Evaluation of sleep disorders in cancer patients based on pittsburgh sleep quality index. Eur J Cancer Care (Engl) 2015;24:553–559. doi: 10.1111/ecc.12296. - DOI - PubMed
    1. Jakobsen G, Engstrom M, Fayers P, Hjermstad MJ, Kaasa S, Kloke M, Sabatowski R, Klepstad P (2019) Sleep quality with WHO Step III opioid use for cancer pain BMJ Supportive & Palliative care 9:307–315 - PubMed
    1. Delgado-Guay M, Yennurajalingam S, Parsons H, Palmer JL, Bruera E. Association between self-reported sleep disturbance and other symptoms in patients with advanced cancer. J Pain Symptom Manag. 2011;41:819–827. doi: 10.1016/j.jpainsymman.2010.07.015. - DOI - PubMed
    1. Mystakidou K, Parpa E, Tsilika E, Gennatas C, Galanos A, Vlahos L. How is sleep quality affected by the psychological and symptom distress of advanced cancer patients? Palliat Med. 2009;23:46–53. doi: 10.1177/0269216308098088. - DOI - PubMed

Publication types

Substances

Associated data